| Larry W Joyce, DO | |
|
2200 E Washington St, Bloomington, IL 61701-4364 | |
| (309) 663-2237 | |
| Not Available |
| Full Name | Larry W Joyce |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 2200 E Washington St, Bloomington, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952354102 | NPI | - | NPPES |
| 0361081541 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 036108154 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Larry W Joyce, DO Po Box 9518, Peoria, IL 61612 Ph: (877) 861-9294 | Larry W Joyce, DO 2200 E Washington St, Bloomington, IL 61701-4364 Ph: (309) 663-2237 |
News Archive
Celsion Corporation announced today that it has completed a critical regulatory step in the countries of China and Japan to rapidly enroll patients in its global Phase III ThermoDox trial for the treatment of Hepatocellular Carcinoma (HCC), also known as primary liver cancer.
A study published in the current issue of Psychotherapy and Psychosomatics evaluates the effectiveness of systems training for emotion control in "real world" patients with borderline personality disorder.
A team of researchers from the Peninsula College of Medicine and Dentistry are part of a wider group of researchers from leading institutions that will implement a -4.7m Policy Research Unit dedicated to achieving early cancer screening and diagnosis. The funding is provided over five years by the Department of Health and will be led by Queen Mary, University of London.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.
› Verified 7 days ago
Renuka Bhaskar, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 105 Krispy Kreme Dr, Ste 4, Bloomington, IL 61704 Phone: 309-585-2837 | |
Lawrence Kohaus, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 2200 E Washington St, Bloomington, IL 61701 Phone: 309-663-2237 | |
Dr. John Scott Denton, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 2708 Piney Run, Bloomington, IL 61705 Phone: 309-830-3483 Fax: 708-469-2536 | |
Louis Boelen, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 2200 E Washington St, Bloomington, IL 61701 Phone: 309-663-2237 | |
Chinbang Li, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 2200 E Washington St, Bloomington, IL 61701 Phone: 309-663-2237 | |
Rejeana Mullins, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 27 Pebblebrook Ct, Bloomington, IL 61705 Phone: 309-820-8767 |